Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study-Reference-Cited by-同舟云学术

Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study

Published:2024-01-22 Issue: Volume: Page:
ISSN:0341-2040
Container-title:Lung
language:en
Short-container-title:Lung

Author:

Pham Duong Duc,Lee Ji-Hyang,Kwon Hyouk-Soo,Song Woo-Jung,Cho You Sook,Kim Hyunkyoung,Kwon Jae-Woo,Park So-Young,Kim Sujeong,Hur Gyu Young,Kim Byung Keun,Nam Young-Hee,Yang Min-Suk,Kim Mi-Yeong,Kim Sae-Hoon,Lee Byung-Jae,Lee Taehoon,Park So-Young,Kim Min-Hye,Cho Young-Joo,Park ChanSun,Jung Jae-Woo,Park Han Ki,Kim Joo-Hee,Moon Ji-Yong,Bhavsar Pankaj,Adcock Ian,Chung Kian Fan,Kim Tae-Bum

Funder

National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00408-024-00670-w.pdf

Reference28 articles.

1. Chung KF, Wenzel SE, Brozek JL et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2):343–373

2. Wang E, Wechsler ME, Tran TN et al (2020) Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest 157(4):790–804

3. Calzetta L, Matera MG, Rogliani P (2019) Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol 15(6):517–520

4. Rogliani P, Calzetta L, Matera MG et al (2020) Severe asthma and biological therapy: when, which, and for whom. Pulm Ther 6(1):47–66

5. Soendergaard MB, Hansen S, Bjerrum AS et al (2022) Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register. ERJ Open Res. https://doi.org/10.1183/23120541.00238-2022